Replimune Group, Inc. — Form 10-K summary
Period: Fiscal year ended March 31, 2019, with comparisons to fiscal 2018 and 2017. The request metadata says “2018 Q4,” but this filing reports FY2019; it also includes unaudited quarterly data for the quarter ended March 31, 2019.
Business context and reporting period
Replimune is a clinical-stage biotechnology company developing oncolytic immunotherapies. It has no approved products and has generated no product-sale revenue. Its lead candidate, RP1, is in a Phase 1/2 program; RP2 and RP3 remain earlier-stage candidates. The financial statements received an unqualified audit opinion from PwC.
Financial results and liquidity
| Metric | FY2019 | FY2018 |
|---|---|---|
| Product revenue | None | None |
| Research and development expense | $22.2 million | $13.5 million |
| General and administrative expense | $8.8 million | $5.7 million |
| Total operating expenses | $30.9 million | $19.2 million |
| Net loss | $30.8 million | $19.7 million |
| Net loss per share, basic and diluted | $1.33 | $3.96 |
| Operating cash used | $25.4 million | $16.0 million |
Revenue-based margins are not meaningful because the company had no product revenue. FY2019 cash and cash equivalents plus short-term investments were $134.8 million, versus $65.0 million a year earlier; working capital was $131.1 million. Total assets were $154.3 million and stockholders’ equity was $137.9 million. The company reported no debt outstanding, but had a $6.6 million financing obligation associated with its build-to-suit facility accounting.
FY2019 investing cash use was $65.9 million, largely reflecting purchases of short-term investments and $2.6 million of property and equipment. Financing provided $101.4 million, principally from the IPO. The IPO and partial over-allotment generated approximately $103.3 million net proceeds. Cash, cash equivalents and restricted cash increased by $9.2 million during the year.
For the March 2019 quarter, operating expenses were $7.8 million, net loss was $6.7 million and loss per share was $0.29. In the March 2018 quarter, operating expenses were $7.1 million, net loss was $7.1 million and loss per share was $1.43.
Material changes versus prior periods
- Annual operating expenses rose $11.7 million, including an $8.7 million increase in R&D and a $3.1 million increase in G&A, reflecting expanded development activity, hiring and public-company costs.
- Net loss increased by $11.1 million. Other income included $2.5 million of UK R&D incentives and $2.6 million of investment income, offset in part by a $5.5 million non-cash warrant fair-value charge. The warrant liability was converted to equity at the July 2018 IPO.
- Cash and short-term investments increased following the IPO, while operating cash use also increased as clinical and operating activities expanded.
- Preferred stock converted into common stock upon the IPO; outstanding preferred stock was zero at March 31, 2019.
Outlook, risks and unusual items
- Management expected continued substantial losses and rising expenses as RP1 trials advance, RP2 and RP3 progress, and the company builds manufacturing capacity. No financial earnings or revenue guidance was provided.
- Management described cash resources as sufficient through at least 12 months from the June 28, 2019 financial-statement issuance date. Elsewhere, the risk discussion projected funding into the second half of calendar 2021. These statements use different horizons and assumptions and should be reconciled.
- The company planned to begin a randomized Phase 2 RP1/cemiplimab trial in cutaneous squamous cell carcinoma, targeting approximately 240 patients, with initiation expected in August 2019. Regeneron was to supply cemiplimab and split trial costs equally.
- RP1 Phase 2 enrollment was open in melanoma, bladder cancer and non-melanoma skin cancer cohorts; the MSI-H/dMMR cohort awaited completion of a Phase 1 expansion enrollment condition. BMS supplied nivolumab at no cost for the RP1 trial but had no further development obligations.
- RP2’s planned Phase 1 start had been delayed by FDA and UK MHRA chemistry, manufacturing and controls queries. Management expected a third-quarter 2019 start, initially in the UK, subject to addressing the requests. RP3 clinical entry was planned for 2020.
- The planned Framingham manufacturing facility was under construction. Management expected clinical-grade production in the first half of 2020; estimated capital expenditure was approximately $22.5 million, net of about $8.9 million in tenant improvements. Delays, qualification and scale-up remain risks.
- Material weaknesses in financial-reporting controls were identified, including insufficient accounting staffing and formal controls for complex transactions. Disclosure controls were deemed ineffective as of March 31, 2019; remediation was underway. Management nevertheless stated the financial statements fairly presented the company’s position and results.
- Other key risks include clinical and regulatory failure, dependence on third-party manufacturing and combination-drug supply, unissued/pending patent applications, future financing needs, reimbursement uncertainty and foreign-exchange exposure. The company reported no material legal proceedings.
Most important facts for investors to verify
- Whether the stated cash runway assumptions remain valid, particularly the difference between the “at least 12 months” statement and the second-half 2021 estimate.
- RP1 trial enrollment, safety and efficacy updates, and the start and design of the planned CSCC randomized study.
- Resolution of FDA/MHRA CMC questions and actual timing for RP2 clinical initiation.
- Framingham facility construction, total capital requirements, regulatory qualification and readiness for clinical-grade production.
- Progress in remediating control weaknesses and the timing and outcome of required internal-control evaluations.
- Facility lease and financing-obligation accounting, manufacturing commitments, and any subsequent financing or share dilution.